From CNBC: 2024-06-21 15:45:56

Eli Lilly has applied for U.S. approval of its weight loss drug Zepbound for obstructive sleep apnea. The company expects a decision by the end of the year and plans to launch the drug at the beginning of 2025. Data from trials presented at a scientific session show Zepbound’s effectiveness at resolving OSA.

Additional data from Eli Lilly’s trials showed that Zepbound helped resolve obstructive sleep apnea in almost half of patients, presenting new hope for treatment. The findings add to evidence of health benefits from weight loss and diabetes treatments. Zepbound has the potential to gain broader insurance coverage for patients.

Obstructive sleep apnea affects an estimated 80 million Americans, with many cases going undiagnosed. Eli Lilly’s Zepbound aims to provide an alternative to cumbersome PAP machines that assist breathing during sleep. The drug has shown promise in resolving the disorder in patients and reducing the severity of OSA.

Zepbound’s positive impact on patient lives is significant, potentially eliminating the need for PAP machines and improving quality of sleep. Studies show that patients who took the drug achieved disease resolution with fewer AHI events per hour. Eli Lilly’s drug demonstrated effectiveness in treating OSA and is fast-tracked for FDA review.



Read more at CNBC: Eli Lilly expects FDA decision on Zepbound for sleep apnea as early as end of year